ReviewMolecular biology reports2026
Molecular mechanisms of herbal medicines and bioactive compounds in rheumatoid arthritis: a comprehensive network pharmacology perspective.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatoid arthritis (RA) is a chronic immune-mediated inflammatory disease characterized by persistent synovial inflammation, progressive joint distruction, and systemic complications. Owing to the multifactorial nature of RA, therapies targeting a single molecular pathway often provide incomplete disease control and may be associated with long-term adverse effects. Network pharmacology has emerged as a powerful system-level approach that integrates bioinformatics, multi-omics datasets, molecular docking, and experimental validation to unravel the complex interactions among bioactive compounds, molecular targets, and signaling pathways. This review highlights the novel application of network pharmacology in deciphering the multi-target mechanisms of herbal medicines for RA and summarizes recent advances in this rapidly evolving field. Particular emphasis is placed on key pathogenic pathways, including NF-κB, PI3K/Akt, MAPK, JAK/STAT, NLRP3 inflammasome activation, oxidative stress responses, angiogenesis, and immune-cell dysregulation. Representative phytochemicals, such as quercetin, kaempferol, luteolin, triptolide, and berberine, are discussed for their ability to modulate inflammatory responses, fibroblast-like synoviocyte activation, macrophage polarization, and osteoclastogenesis through coordinated regulation of multiple signaling networks. Importantly, this review underscores the translational significance of network pharmacology as a bridge between traditional herbal medicine and modern drug discovery, facilitating target prioritization, mechanism-based validation, and the rational development of multi-target therapeutics for RA. Collectively, network pharmacology provides a robust framework for the mechanistic interpretation of herbal medicines and offers a promising opportunity to accelerate the discovery and clinical translation of safer, more effective therapies for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.